Cns Pharmaceuticals Inc (CNSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 5,111 | 10,055 | 7,028 | 8,959 | 12,441 |
| TOTAL | $6,972 | $12,565 | $8,700 | $11,397 | $14,733 |
| Non-Current Assets | |||||
| PPE Net | 4 | 6 | 9 | 11 | 13 |
| Other Non-Current Assets | 438 | 483 | 929 | 1,039 | 1,126 |
| TOTAL | $443 | $489 | $938 | $1,050 | $1,139 |
| Total Assets | $7,415 | $13,053 | $9,638 | $12,447 | $15,872 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,781 | 4,510 | 1,005 | 491 | 490 |
| Accrued Expenses | 853 | N/A | 200 | 277 | 307 |
| TOTAL | $3,923 | $4,920 | $1,244 | $924 | $1,069 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $3,923 | $4,920 | $1,244 | $924 | $1,069 |
| Shareholders' Equity | |||||
| Common Shares | 2 | 2 | 40 | 40 | 40 |
| Retained earnings | -55,648 | -50,716 | -44,753 | -41,333 | -37,767 |
| TOTAL | $3,492 | $8,133 | $8,394 | $11,524 | $14,803 |
| Total Liabilities And Equity | $7,415 | $13,053 | $9,638 | $12,447 | $15,872 |